Gut bacteria compound may play a role in Alzheimer’s
A compound produced by gut bacteria may contribute to brain changes involved in Alzheimer’s disease. In mice it increased the build-up of harmful brain proteins, and in people high levels went with faster cognitive decline. The findings suggest the gut plays an active role in dementia development.
Researchers studied a molecule called imidazole propionate (ImP), produced by certain gut bacteria when breaking down the amino acid histidine. The study found that in mice, ImP reaching the brain increased the build-up of abnormal amyloid and tau. In almost 1,200 people, higher ImP levels in the blood went with more markers of abnormal proteins and impaired nerve cell function. Both are hallmarks of Alzheimer’s disease.
In people, the study shows a correlation, not a causal relationship. Still, the association is striking. People with higher ImP concentrations also showed faster decline in memory and other cognitive functions. From a longevity perspective, this is notable because it points to a potential new target outside the brain itself.
From gut to brain
The idea that gut bacteria influence the brain through their metabolic products is known as the gut-brain axis. Gut bacteria continuously produce compounds that reach the entire body via the bloodstream. ImP is one such compound. Earlier research had already linked ImP to type 2 diabetes and coronary artery disease.
The researchers suggest that lowering ImP levels in the blood could potentially have a protective effect. How that might work in practice remains unclear. Diet is a difficult route: bacteria make ImP from histidine, an amino acid you need that is found in many protein-rich foods. The researchers are thinking instead of a drug that lowers ImP in the blood, the way a statin does for cholesterol. This remains speculative and requires further investigation.
A new direction in dementia research
Alzheimer’s research has traditionally focused on the brain itself: clearing plaques, inhibiting tau phosphorylation, protecting neurons. This research adds a different layer. If a bacterial byproduct in the gut genuinely contributes to brain deterioration, it opens the way to drugs that lower ImP in the blood.
It is important to keep the findings in perspective. The human data are correlations, and the effect on the brain was measured in mice. Whether reducing ImP also slows cognitive decline must be demonstrated in future research.
Search terms to explore further: gut-brain axis Alzheimer’s | imidazole propionate cognition | microbiome amyloid plaques